Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses.

Broséus J, Chen G, Hergalant S, Ramstein G, Mounier N, Guéant JL, Feugier P, Gisselbrecht C, Thieblemont C, Houlgatte R.

Oncotarget. 2016 Dec 20;7(51):83987-84002. doi: 10.18632/oncotarget.9793.

2.

Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.

Cani AK, Hovelson DH, Demirci H, Johnson MW, Tomlins SA, Rao RC.

Oncotarget. 2017 Jan 31;8(5):7989-7998. doi: 10.18632/oncotarget.14008.

3.

Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.

Cao Y, Zhu T, Zhang P, Xiao M, Yi S, Yang Y, Li Q, Ling S, Wang Y, Gao L, Zhu L, Wang J, Wang N, Huang L, Zhang P, Zhai Q, Qiu L, Zhou J.

Oncotarget. 2016 Dec 13;7(50):83294-83307. doi: 10.18632/oncotarget.13065.

4.

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.

Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C.

J Clin Oncol. 2011 Nov 1;29(31):4079-87. doi: 10.1200/JCO.2011.35.4423. Epub 2011 Sep 26.

PMID:
21947824
5.

High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy.

Kreisel F, Kulkarni S, Kerns RT, Hassan A, Deshmukh H, Nagarajan R, Frater JL, Cashen A.

Cancer Genet. 2011 Mar;204(3):129-37. doi: 10.1016/j.cancergen.2010.12.010.

6.
7.

Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma.

Taskinen M, Louhimo R, Koivula S, Chen P, Rantanen V, Holte H, Delabie J, Karjalainen-Lindsberg ML, Björkholm M, Fluge Ø, Pedersen LM, Fjordén K, Jerkeman M, Eriksson M, Hautaniemi S, Leppä S.

PLoS One. 2014 Mar 13;9(3):e91031. doi: 10.1371/journal.pone.0091031. eCollection 2014.

8.

Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.

Lee AY, Connors JM, Klimo P, O'Reilly SE, Gascoyne RD.

J Clin Oncol. 1997 May;15(5):1745-53.

PMID:
9164181
9.

Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.

Guo L, Lin P, Xiong H, Tu S, Chen G.

Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):85-96. doi: 10.1016/j.bbcan.2018.01.001. Epub 2018 Jan 11. Review.

PMID:
29337112
10.

Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).

Carreras J, Kikuti YY, Beà S, Miyaoka M, Hiraiwa S, Ikoma H, Nagao R, Tomita S, Martin-Garcia D, Salaverria I, Sato A, Ichiki A, Roncador G, Garcia JF, Ando K, Campo E, Nakamura N.

Histopathology. 2017 Mar;70(4):595-621. doi: 10.1111/his.13106. Epub 2017 Jan 9.

PMID:
27775850
11.

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.

Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A.

Blood Cancer J. 2018 Jun 12;8(6):60. doi: 10.1038/s41408-018-0089-0.

12.

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.

Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, Shovlin M, Jaffe ES, Janik JE, Staudt LM, Wilson WH.

Blood. 2009 Jun 11;113(24):6069-76. doi: 10.1182/blood-2009-01-199679. Epub 2009 Apr 20.

13.

LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.

Peng W, Wu J, Feng J.

Clin Exp Med. 2017 Feb;17(1):1-8. doi: 10.1007/s10238-015-0396-8. Epub 2015 Oct 16.

PMID:
26475621
14.

Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma.

Modvig L, Vase M, d'Amore F.

Br J Haematol. 2017 Oct;179(1):75-82. doi: 10.1111/bjh.14822. Epub 2017 Jun 27.

PMID:
28653321
15.

Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma.

Cui W, Cai Y, Wang W, Liu Z, Wei P, Bi R, Chen W, Sun M, Zhou X.

J Transl Med. 2014 Jan 13;12:10. doi: 10.1186/1479-5876-12-10.

16.

Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.

Gong QX, Lu TX, Liu C, Wang Z, Liang JH, Xu W, Li JY, Zhang ZH, Chen Q.

Int J Clin Exp Pathol. 2015 Dec 1;8(12):15825-35. eCollection 2015.

17.

Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways.

Booman M, Szuhai K, Rosenwald A, Hartmann E, Kluin-Nelemans H, de Jong D, Schuuring E, Kluin P.

J Pathol. 2008 Oct;216(2):209-17. doi: 10.1002/path.2399.

PMID:
18729069
18.

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM.

N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.

19.

Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis.

Scholtysik R, Kreuz M, Hummel M, Rosolowski M, Szczepanowski M, Klapper W, Loeffler M, Trümper L, Siebert R, Küppers R; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe.

Int J Cancer. 2015 Mar 1;136(5):1033-42. doi: 10.1002/ijc.29072. Epub 2014 Jul 22.

20.

Diffuse large B-cell lymphoma with MYC gene rearrangements: Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature.

de Jonge AV, Roosma TJ, Houtenbos I, Vasmel WL, van de Hem K, de Boer JP, van Maanen T, Lindauer-van der Werf G, Beeker A, Timmers GJ, Schaar CG, Soesan M, Poddighe PJ, de Jong D, Chamuleau ME.

Eur J Cancer. 2016 Mar;55:140-6. doi: 10.1016/j.ejca.2015.12.001. Epub 2016 Jan 25. Review.

PMID:
26820684

Supplemental Content

Support Center